Movement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound

Market Focus06-04

On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.

On the news front, the company recently released multiple positive developments that converged to extend the stock's rebound momentum. The company's independently developed circular RNA-encoded GLP-1 analogue CR059 research was accepted by the 62nd European Association for the Study of Diabetes annual meeting and selected for an oral discussion session. Additionally, its core commercial product Vepegnatide Injection was included in the 2026 second batch of reference drug pre-communication supplementary disclosure by China's National Healthcare Security Administration, strengthening medical insurance access expectations. The board also proposed a general mandate to repurchase up to 10% of issued H-shares, pending shareholder approval on June 24.

These multiple catalysts, combined with the full release of lock-up selling pressure following the one-year post-IPO share restriction expiry in late May, collectively propelled the stock's continued recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152329611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 13:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152329611","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound","media":"Market Focus","content":"<p><p>On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.</p><p>On the news front, the company recently released multiple positive developments that converged to extend the stock's rebound momentum. The company's independently developed circular RNA-encoded GLP-1 analogue CR059 research was accepted by the 62nd European Association for the Study of Diabetes annual meeting and selected for an oral discussion session. Additionally, its core commercial product Vepegnatide Injection was included in the 2026 second batch of reference drug pre-communication supplementary disclosure by China's National Healthcare Security Administration, strengthening medical insurance access expectations. The board also proposed a general mandate to repurchase up to 10% of issued H-shares, pending shareholder approval on June 24.</p><p>These multiple catalysts, combined with the full release of lock-up selling pressure following the one-year post-IPO share restriction expiry in late May, collectively propelled the stock's continued recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Rises 8.52% in Regular Trading, Multiple Positive Catalysts Drive Continued Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 13:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.</p><p>On the news front, the company recently released multiple positive developments that converged to extend the stock's rebound momentum. The company's independently developed circular RNA-encoded GLP-1 analogue CR059 research was accepted by the 62nd European Association for the Study of Diabetes annual meeting and selected for an oral discussion session. Additionally, its core commercial product Vepegnatide Injection was included in the 2026 second batch of reference drug pre-communication supplementary disclosure by China's National Healthcare Security Administration, strengthening medical insurance access expectations. The board also proposed a general mandate to repurchase up to 10% of issued H-shares, pending shareholder approval on June 24.</p><p>These multiple catalysts, combined with the full release of lock-up selling pressure following the one-year post-IPO share restriction expiry in late May, collectively propelled the stock's continued recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1152329611","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152329611","pubTimestamp":1780551768,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.On the news front, the company recently released multiple positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"动向提示|派格生物常规交易涨8.52%多重利好催化推动持续反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On June 4, PegBio (02565.HK) rose 8.52% in regular trading, trading at HKD 8.69/share, with trading volume of HKD 142 million.On the news front, the company recently released multiple positive developments that converged to extend the stock's rebound momentum. The company's independently developed circular RNA-encoded GLP-1 analogue CR059 research was accepted by the 62nd European Association for the Study of Diabetes annual meeting and selected for an oral discussion session. Additionally, its core commercial product Vepegnatide Injection was included in the 2026 second batch of reference drug pre-communication supplementary disclosure by China's National Healthcare Security Administration, strengthening medical insurance access expectations. The board also proposed a general mandate to repurchase up to 10% of issued H-shares, pending shareholder approval on June 24.These multiple catalysts, combined with the full release of lock-up selling pressure following the one-year post-IPO share restriction expiry in late May, collectively propelled the stock's continued recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152329611","isCrawlerRequest":true}